Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 Mar 5;29(3):110-115.
doi: 10.2188/jea.JE20170241. Epub 2018 Jul 14.

Impact of Comorbidities on Survival in Gastric, Colorectal, and Lung Cancer Patients

Affiliations
Free PMC article
Multicenter Study

Impact of Comorbidities on Survival in Gastric, Colorectal, and Lung Cancer Patients

Toshitaka Morishima et al. J Epidemiol. .
Free PMC article

Abstract

Background: The presence of comorbidities in cancer patients may influence treatment decisions and prognoses. This study aimed to examine the impact of comorbidities on overall survival in Japanese patients diagnosed with major solid tumors.

Methods: To obtain patient-level information on clinical conditions and vital status, we performed a record linkage of population-based cancer registry data from Osaka Prefecture, Japan and administrative data produced under the Diagnosis Procedure Combination (DPC) system. The study population comprised patients who received a primary diagnosis of gastric, colorectal, or lung cancer between 2010 and 2012 at any of five cancer centers. We employed the Charlson Comorbidity Index (CCI) score to quantify the impact of comorbidities on survival. The association between CCI score and survival for each cancer site was analyzed using Cox proportional hazards regression models for all-cause mortality, after adjusting for patient sex, age at cancer diagnosis, and cancer stage.

Results: A total of 2,609 patients with a median follow-up duration of 1,372 days were analyzed. The most frequent CCI score among the patients was 0 (77.7%), followed by 2 (14.3%). After adjusting for the covariates, we detected a significant association between CCI score and all-cause mortality. The hazard ratios per one-point increase in CCI score were 1.12 (95% confidence interval [CI], 1.02-1.23), 1.20 (95% CI, 1.08-1.34), and 1.14 (95% CI, 1.04-1.24) for gastric, colorectal, and lung cancer, respectively.

Conclusions: Comorbidities have a negative prognostic impact on overall survival in cancer patients, and should be assessed as risk factors for mortality when reporting outcomes.

Keywords: administrative claims data; comorbidity; medical record linkage; neoplasms; survival analysis.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–1314. 10.1002/cncr.28509 - DOI - PMC - PubMed
    1. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol. 2001;19:1147–1151. 10.1200/JCO.2001.19.4.1147 - DOI - PubMed
    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765. 10.1200/JCO.2008.20.8983 - DOI - PubMed
    1. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–724. 10.1001/jama.294.6.716 - DOI - PubMed
    1. Lee M, Cronin KA, Gail MH, Feuer EJ. Predicting the absolute risk of dying from colorectal cancer and from other causes using population-based cancer registry data. Stat Med. 2012;31:489–500. 10.1002/sim.4454 - DOI - PubMed

Publication types

Feedback